Join the Osteolytic Bone Lesions of Multiple Myeloma group to help and get support from people like you.
Osteolytic Bone Lesions of Multiple Myeloma News
Related terms: Multiple Myeloma, Osteolytic Bone Lesions
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
TUESDAY, April 9, 2024 – The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory...
Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma
FRIDAY, Feb. 9, 2024 – For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes,...
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 – For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and...
Racial, Ethnic Differences ID'd for Idecabtagene Vicleucel in Multiple Myeloma
WEDNESDAY, Oct. 25, 2023 – There are some racial and ethnic differences in safety and response to standard of care (SOC) idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory...
Younger Patients With Multiple Myeloma Can Achieve Durable Survival
THURSDAY, July 27, 2023 – Younger adults with newly diagnosed multiple myeloma who receive an autologous stem cell transplant (auto-HCT) have a median progression-free survival (PFS) of...
FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
Ask a question
To post your own question to this support group, sign in or create an account.